SG11201811223YA - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SG11201811223YA
SG11201811223YA SG11201811223YA SG11201811223YA SG11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA
Authority
SG
Singapore
Prior art keywords
international
pct
yield
publication
date
Prior art date
Application number
SG11201811223YA
Inventor
Corswant Christian Von
Romain Bordes
Jonasson Simon Hjelm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201811223YA publication Critical patent/SG11201811223YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1111111111110110101011111011110111111111 111MEMME 11101111 (10) International Publication Number WO 2018/015175 A9 W O 20 18/0 15 175 A9 25 January 2018 (25.01.2018) W 1 PO I PCT (51) International Patent Classification: A61K 9/16 (2006.01) A61K 36/48 (2006.01) A61K 31/201 (2006.01) A61K 9/20 (2006.01) A61K 31/202 (2006.01) (21) International Application Number: PCT/EP2017/066983 (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1611920.8 08 July 2016 (08.07.2016) GB (71) Applicant: ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE). (72) Inventors: VON CORSWANT, Christian; AstraZeneca AB, SE-431 83 Molndal (SE). BORDES, Romain; Chalmers tekniskahogskola AB Kemivagen 4, 412 96 Gote- borg (SE). HJELM JONASSON, Simon, Peter, Michael; Chalmers tekniska hogskola AB Kemivagen 4, 412 96 Gote- borg (SE). (74) Agent: TTOFI, Evangelia; Medlmmune Limited Milstein Building, Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: PHARMACEUTICAL COMPOSITIONS 90 80 70 60 .13 50 40 30 20 10 0 O Cyclone Yield • Collemor Yield 4-1-S 4-1-0 4-0.5 S 4 0.5 0 2 1 S 2-1-2 0.5-S 2-0.5-0 Emulsion Composition Figure 1. Yield for the spray - drying process of eight batches with varying compositions. (57) : The present application relates to solid pharmaceutical compositions and solid dosage forms containing them which comprise oils as their active pharmaceutical ingredient. Methods of preparing the compositions and their uses are described. [Continued on next page] WO 2018/015175 A9 IMEDIM011111 11111111EIDIO0 IIM11111111111111111111110111111111111 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) (48) Date of publication of this corrected version: 29 March 2018 (29.03.2018) (15) Information about Correction: see Notice of 29 March 2018 (29.03.2018)
SG11201811223YA 2016-07-08 2017-07-06 Pharmaceutical compositions SG11201811223YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1611920.8A GB201611920D0 (en) 2016-07-08 2016-07-08 Pharmaceutical compositions
PCT/EP2017/066983 WO2018015175A1 (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SG11201811223YA true SG11201811223YA (en) 2019-01-30

Family

ID=56890842

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811223YA SG11201811223YA (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Country Status (20)

Country Link
US (1) US20200254046A1 (en)
EP (1) EP3481377A1 (en)
JP (1) JP2019520393A (en)
KR (1) KR20190026816A (en)
CN (1) CN109414409A (en)
AU (1) AU2017298873B2 (en)
BR (1) BR112019000240A2 (en)
CA (1) CA3029331A1 (en)
CL (1) CL2019000042A1 (en)
CO (1) CO2019000083A2 (en)
CR (1) CR20190007A (en)
DO (1) DOP2019000002A (en)
EA (1) EA201990162A1 (en)
GB (1) GB201611920D0 (en)
IL (1) IL263999A (en)
MX (1) MX2019000255A (en)
PE (1) PE20190321A1 (en)
PH (1) PH12019500024A1 (en)
SG (1) SG11201811223YA (en)
WO (1) WO2018015175A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071461A1 (en) * 2020-10-02 2022-04-07 住友精化株式会社 Viscous composition
WO2022071463A1 (en) * 2020-10-02 2022-04-07 住友精化株式会社 Viscous composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382597T1 (en) * 2002-06-17 2008-01-15 Resolvyx Pharmaceuticals ANALOGUE OF OMEGA-3 PUFAS DERIVED LIPID MEDIATORS AND METHODS OF APPLICATION
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate
JP6176894B2 (en) * 2009-03-09 2017-08-09 プロノヴァ・バイオファーマ・ノルゲ・アーエス Composition comprising fatty acid oil mixture and surfactant, and method and use thereof
CN102512664B (en) * 2010-12-31 2015-04-01 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition
EP3348262A1 (en) 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form

Also Published As

Publication number Publication date
GB201611920D0 (en) 2016-08-24
PH12019500024A1 (en) 2019-11-04
WO2018015175A9 (en) 2018-03-29
KR20190026816A (en) 2019-03-13
US20200254046A1 (en) 2020-08-13
CO2019000083A2 (en) 2019-01-18
JP2019520393A (en) 2019-07-18
CR20190007A (en) 2019-03-05
AU2017298873B2 (en) 2020-04-30
AU2017298873A1 (en) 2019-02-14
PE20190321A1 (en) 2019-03-04
CA3029331A1 (en) 2018-01-25
IL263999A (en) 2019-01-31
EP3481377A1 (en) 2019-05-15
BR112019000240A2 (en) 2019-04-16
CN109414409A (en) 2019-03-01
CL2019000042A1 (en) 2019-04-12
EA201990162A1 (en) 2019-06-28
DOP2019000002A (en) 2019-03-31
MX2019000255A (en) 2019-05-27
WO2018015175A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201809751XA (en) Egfr inhibitor compounds
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201909011PA (en) Niraparib compositions
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906222WA (en) Jak1 selective inhibitors
SG11201805001UA (en) Method of treating influenza a
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201804587QA (en) Isoindole compounds
SG11202000494UA (en) Drug delivery composition
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders